Press

TrialEngage-AGA

TrialEngage-AGA

Rx.Health's TrialEngage™ Virtual Trial Toolkit is Selected by the American Gastroenterological Association to Speed GITrials and Create Nationwide Clinical Trial Network With our partners, we have developed a unique ecosystem to support centres for excellence in...

COVAXIN TM

COVAXIN TM

COVAXIN™,  India's indigenous  COVID-19  vaccine by  Bharat  Biotech is developed in collaboration with the  Indian  Council of  Medical  Research  (ICMR) -National  Institute of  Virology  (NIV).  The indigenous, inactivated vaccine is developed and manufactured in...

Remdesivir for treatment of severe COVID-19

Remdesivir for treatment of severe COVID-19

The broad-spectrum antiviral agent remdesivir (GS-5734; Gilead Sciences, Inc) is an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV). The US FDA issued EUA (Emergency use...

Rx.Health supports the Mount Sinai lead stop NYC program

Rx.Health supports the Mount Sinai lead stop NYC program

We need to learn more about COVID-19 to stop it. The goal is to identify the infection, transmission and track the patients in NYC. Researchers at Mount Sinai tracking COVID-19 in New York City with STOP COVID NYC. The app uses web-based surveys to collect data from...

We promise we don’t send spam

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!